Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Viking Thera (NQ: VKTX ) 76.97 +4.09 (+5.61%) Streaming Delayed Price Updated: 9:40 AM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Viking Thera Is Viking Therapeutics Ready For Another Surge? September 27, 2024 Viking Therapeutics' promising weight loss drug could revolutionize the obesity market and propel the company's stock price to new highs. Via MarketBeat Viking Therapeutics Is Having a Year to Remember: Time to Buy? September 19, 2024 Viking Therapeutics Inc. (NASDAQ: VKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market. Via MarketBeat Viking Therapeutics: Pharma Stock Soars on Positive Earnings July 25, 2024 Viking Therapeutics stock soars on clinical trial results and a solid earnings beat, signaling a potential market shake-up in the biopharmaceutical sector. Via MarketBeat Topics Earnings Exposures Financial Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug July 09, 2024 Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been Via MarketBeat Viking Therapeutics Inc. (NASDAQ: VKTX) is a Stock Spotlight on 5/23 May 23, 2023 Via Investor Brand Network Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer? July 03, 2024 Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases Via MarketBeat Exposures Product Safety Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes July 02, 2024 Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy Via MarketBeat Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market July 01, 2024 Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Via MarketBeat Exposures Product Safety Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon May 06, 2024 Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs Via MarketBeat Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? April 22, 2024 The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio Via MarketBeat Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 09, 2024 Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market Via MarketBeat Exposures Product Safety MarketBeat Week in Review – 4/1 - 4/5 April 06, 2024 Equities lost ground this week as investors consider the effect of fewer rate cuts, rising oil prices, and robust job gains ahead of a new earnings season Via MarketBeat Topics Economy Exposures Interest Rates Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill April 03, 2024 Viking Therapeutics is preparing to be the next entry into the GLP-1 Market, and VKTX stock is soaring as analysts start to bid the stock higher Via MarketBeat Exposures Product Safety 7 Stocks That Will Drive the Weight Loss Drugs Market March 28, 2024 The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis. Via MarketBeat Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant March 06, 2024 The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher Via MarketBeat Exposures Product Safety Viking Therapeutics Inc. (NASDAQ: VKTX) Near Top of Volume Charts in Tuesday Trading February 27, 2024 Via Investor Brand Network 2 biotechs with promising weight-loss drugs coming January 16, 2024 Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. Via MarketBeat Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders October 19, 2023 EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END Via FinancialNewsMedia Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush July 24, 2023 A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies. Via MarketBeat Here are 2 Top Drug Makers Leading the Way in Weight Loss Drugs April 17, 2023 The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatme Via MarketBeat Viking Therapeutics Inc. (NASDAQ: VKTX) Records 52-Week High Tuesday Morning March 28, 2023 Via Investor Brand Network Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data March 28, 2023 Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP Via MarketBeat Why Did Viking Therapeutics Stock Skyrocket December 21, 2022 VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial. Via MarketBeat Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
